Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.
Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in theBRAF-mutant colorectal cancer patient population.
The most recent study presented for theBRAF-mutant population was SWOG S1406, which looked at a control arm of irinotecan and cetuximab with or without vemurafenib inBRAF-mutant metastatic colorectal cancer. The study was positive for progression-free survival, which was the primary endpoint.
Eng believes this was an eye-opening study in that it suggests testing patients for the presence of aBRAFmutation and providing patients with a BRAF inhibitor.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More